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Edited by Veli-Pekka LehtoAbstract Here we report a new model of pre-clinical breast
cancer which has been generated by overexpressing the steroid
receptor coactivator AIB1 at moderate levels in breast epithe-
lium. Transgenic female mice display mammary hyperplasia at
the onset of puberty, consistent with enhanced proliferation of
primary mammary epithelial cultures and augmented levels of
cyclin D1 and E-cadherin. Studies of BrdU incorporation re-
vealed that AIB1 localizes to the nucleus during or after S phase,
implicating a new role for AIB1 in cell-cycle progression subse-
quent to G1. Our ﬁndings suggest that moderate overexpression
of AIB1 may represent one of the pre-neoplastic changes in
breast tissue.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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E-cadherin1. Introduction
Tumor progression is a multi-step process by which gain of
chromosome instabilities and modiﬁcations drive the positive
selection of the cancerous cells. To study this process of tumor
development, a broad variety of animal models have been
developed harboring modiﬁed oncogenes and tumor suppres-
sor genes. It is believed that these original modiﬁcations are
responsible for chromosome instability and thus, favor the
new genetic changes that deﬁne cancer progression. AIB1
(SRC-3/p/CIP/ACTR/RAC3/TRAM-1) [1–6] is a nuclear
receptor coactivator that is overexpressed in several types of
cancers including breast and ovarian cancer [1,7], prostate
[8], gastric [9], pancreas [10,11] and liver [12]. In human breast
cancer cell lines such as MCF-7 AIB1 is a major coactivator
for the estrogen receptor (ER) [13]. We have recently shown
that overexpression of the esteroid receptor coactivator AIB1
in the murine mammary gland results in the development of
adenocarcinomas of diﬀerent subtypes [14]. In contrast,
AIB1 ablation impairs mammary tumorogenesis [15] indicat-
ing that AIB1 is an oncogene.*Corresponding author. Fax: +34 96 328 9701.
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doi:10.1016/j.febslet.2006.08.057Several mechanisms have been postulated to explain the
role(s) of AIB1 breast cancer. Consistent with data from
knock-out mice [16], we have observed that transgenic mice
overexpressing AIB1 display increased levels of IGF-I, thereby
augmenting the IGF-I signaling pathways [14]. However, the
function of AIB1 in IGF-I-mediated signaling, proliferation
and cell survival in human breast cancer cells is independent
of its role in estrogen receptor signaling [17]. Other studies have
demonstrated a more direct role in cell-cycle machinery; AIB1
is an important factor in regulating the activated promotor of
cyclin D1 [18] and furthermore, promotes cell-cycle progression
and cell survival by coactivating the transcriptional factors
E2F1 and ER81 [19,20]. E2F1 is a key regulator of the cell cycle
that mediates G1 progression; AIB1 can function as a coactiva-
tor by stimulating the transcription of a subset of E2F-respon-
sive genes that are associated with the G1/S transition.2. Materials and methods
2.1. Generation of mice
Transgenic mice were generated as previously described [14] on a
C57/Bl6 genetic background. Integration of the transgene into the gen-
ome of the oﬀspring was assessed by Southern blot and PCR analysis
of genomic DNA from tail biopsies using the following primers
5 0GGCCCCGGCCCCCAAGCTTG3 0 and 5 0CGTGAATCACTGG-
CCAGTGGATCC3 0.
2.2. Real-time PCR
Isolated RNA (TRIzol, Invitrogen) from tissues was digested with
DNAse followed by puriﬁcation through QIAGEN columns (RNeasy
kit). Subsequently, the RT reaction (Superscript, Invitrogen) was done
with 0.5 lg of total RNA and oligo (dT). Real Time-PCR was per-
formed with 10 ng cDNA using the oligos: 5 0GGCCAGTGAT-
TCACGAAAACG3 0 and 5 0ACTTTCCTGCTCCCGTCTCC3 0 for
AIB1; 5 0CAAATGCTGGACCAAACACAA30 and 5 0GCCATCCA-
GCCACTCAGTCT3 0 for cyclophilin; 5 0GCTCCCGTCTCCGTT-
TTTCT3’ and 5’ATTTGCTGAACAGTGGACTCC3’ for p/CIP.
2.3. In vivo BrdU labeling
Four hours before sacriﬁce, WT and AIB1-tg mice at 10 weeks of
age were injected with 100 lg/g of body weight of BrdU (Sigma). Tis-
sues were ﬁxed for 6 h in 10% neutralized buﬀered formalin and
embedded in paraﬃn by standard procedures. Sections of 5 lm thick-
ness were processed for immunohistochemistry analysis following
antigen retrieval.
2.4. Antibodies
Cross-sections were stained with Rat anti-BrdU antibody (Accurate
Chemical & Scientiﬁc Corp.) and counterstained with hematoxylin.blished by Elsevier B.V. All rights reserved.
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p/CIP was generated in our laboratory. Monoclonal anti-AIB1 that
recognizes primarily human AIB1, anti-E-Cadherin (1:1000; BD
Transduction Laboratories). Monoclonal b-tubulin (D-10), monoclo-
nal cyclin D1 (72-13G) and goat polyclonal CK14 (Santa Cruz).
2.5. Primary cultures and small interfering RNA (siRNA)
Mammary glands from 12-week-old virgin females were collected
from sacriﬁced animals, carefully minced in DMEM/F12 media with-
out serum and digested with 2 mg/ml Collagenase A (Boehringer–
Mannheim) for 30 min at 37 C. Digested tissue was washed once
and resuspended in DMEM/F12 media supplemented with 10% FBS,
5 lg/ml insulin, 10 lg/ml hydrocortisone, 10 ng/ml murine EGF and
5 lg/ml linoleic acid. Mammary epithelial cells were grown in incuba-
tors at 37 C with 5% CO2. Duplex siRNA oligonucleotides (100 nM)
targeting siAIB1 mRNA 5 0AGACUCCUUAGGACCGCUUdTdT3 0
(Ambion) was transfected using Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s instructions. Cells were harvested
48 h post-transfection. Cells were lysed in ice-cold RIPA buﬀer includ-
ing protease inhibitor cocktail (Roche). Lysates were centrifuged at
14000 rpm for 15 min 50 lg of protein was separated on SDS–PAGE
gel and transferred to nylon membranes.
2.6. Laser Scanning Cytometry (LSC)
Primary cells were seeded in chamber slides. Media were replaced
next day and cultures were incubated for another 24 h. Cells were
washed with PBS and ﬁxed with 70% ethanol for 30 min at 4 C. Cells
were then washed three times with PBS and incubated for 30 min with
a solution of PBS containing 0.1 mg/ml RNAse A, 50 lg/ml propidium
iodide and 0.1% Triton X-100. Cells were covered with Dako ﬂuores-
cent mounting media containing 50 lg/ml of propidium iodide and
ﬂuorescence was determined in a CompuCyte Laser Scanning Cyto-
meter.3. Results and discussion
Genetically modiﬁed animals constitute powerful tools for
in vivo studies of human pathologies and drug development.
To better understand the contribution of AIB1 in mammary
gland development and in breast cancer, we have analyzed
the cellular and biochemical consequences of overexpressingFig. 1. Mammary hyperplasia in AIB1 transgenic mice. Whole mount stainin
stages of development: (A) 4-week-old virgins, n = 6 WT and 6 AIB1-tg; (B)
n = 3 WT controls and 3 AIB1-tg. Right panels represent a magniﬁcation of
dissected, mounted on glass slides, and stained as described at http://mammlow levels of AIB1 in the mouse breast epithelium. In contrast
to previous reported lines where transgenic mice consistently
expressed high levels of AIB1 plus p/CIP expression as com-
pared with WT animals (7.6 fold increase) [14], here we study
a transgenic line with only a 2.5 ± 0.3 fold increase (P = 0.01 in
a paired t-test) in recombinant AIB1 expression. Similar to this
previous report, AIB1 and endogenous p/CIP mRNA levels
were determined in mammary glands of tg animals at 10 weeks
of age using real-time PCR and primers speciﬁc for p/CIP or
AIB1. Results were normalized with cyclophilin and averaged
for four diﬀerent experiments.
A total of 28 AIB1-tg and 22 WT females were maintained
for at least two years to study the development of tumors.
No diﬀerences were observed between these two experimental
groups, indicating that low levels of AIB1 overexpression are
not suﬃcient to trigger the full development of tumors. How-
ever, ductal outgrowth was consistently increased in AIB1-tg
mice. Beginning with the early stages of puberty (4-weeks-
old, Fig. 1A), AIB1-tg epithelium exhibited extensive ductal
branching with prominent terminal end buds (TEBs). In con-
trast to WT control females, ductal outgrowth extended fur-
ther than the lymph node in all AIB1-tg mice and TEBs
displayed an increase in number as well as size (compare mag-
niﬁed panels on the right of Fig. 1). These characteristics of the
AIB1-tg epithelium also persisted in fully mature mammary
glands (Fig. 1B); at 12 weeks of age, mammary epithelium in
AIB1-tg also exhibited increased fat pad occupancy as well
as secondary branching. Following this pattern of develop-
ment, nursing AIB1-tg mammary glands displayed higher
occupancy of the fat pad (Fig. 1C). These results demonstrate
that even small increases in AIB1 expression may signiﬁcantly
augment lateral branching and TEBs during development and
increase epithelial content of the fat pad at maturity.
We further quantiﬁed the percentage of ﬁlled fat pad during
adulthood. Consistent with the morphology, AIB1-tg dis-
played a 25% increase in the area occupied by the fat pad
(Fig. 2A). This increased occupancy of the fat pad correlatedg of transgenic and wildtype mammary glands of littermates at diﬀerent
12-week-old virgins, n = 6 WT and 6 AIB1-tg; (C) lactating mothers,
the framed area in the whole mammary gland. Mammary glands were
ary.nih.gov/tools/histological/Histology/index.html.
Fig. 2. Increased fat pad occupancy and cell proliferation in AIB1-tg. (A) Percentage of ﬁlled fat pad (PFPF) was measured in three 10-week-old WT
and three AIB1-tg littermates by the ductal system of outgrowth. PFPF was estimated by measuring the distance the ductal outgrowth extended
across the fat pad divided by the length of the fat pad. *P = 0.02. (B) BrdU incorporation was measured by counting positive nuclei in mammary
gland tissue sections. DAPI-stained nuclei were scored as a reference for total cell number. The number of BrdU-positive cells in WT and AIB1-tg
samples was counted in 10 ﬁelds per slide, under 20· magniﬁcation. Final results represent the average of 3 independent experiments, representing a
total of 9 WT controls and 9 AIB1-tg. **P = 0.04.
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AIB1-tg epithelial cells have an increased proliferation rate,
thereby providing an explanation for the greater occupancy
of the fat pad. These observations suggest a role for AIB1 in
pre-tumoral lesions and demonstrate that sub-clinical levels
of AIB1 overexpression in mammary epithelial cells produces
hyperplasia and indicates that additional genetic/epigenetic
modiﬁcations are subsequently required to trigger and develop
breast tumors.
Interestingly, staining with antibodies which detect both
AIB1 and p/CIP revealed that incorporation of BrdU corre-
lated strongly with nuclear localization of AIB1 (Fig. 3). This
observation was similar in both transgenic and control animals
(compare upper panels versus lower panels), although both
nuclear localization and proliferation were more frequent in
AIB1-tg (Figs. 2B and 3B). This correlation between prolifer-
ation and nuclear staining for AIB1 was independent of the
status of mammary gland development as we observed this
relationship in females of puberty, adulthood and lactation
(Fig. 3A). Since BrdU incorporation occurs during S-phase
of the cell cycle, these studies suggest that nuclear import of
AIB1 is a general mechanism that occurs predominantly dur-
ing or after S-phase. Consistent with this notion, non-prolifer-
ative cells contained lower levels of AIB1 which were restricted
to the cytoplasm (Fig. 3). However, AIB1 expression potently
increased in proliferative cells, consistent with a recent report
[20] demonstrating a feedback loop whereby AIB1 levels are
elevated at G1/S phase through coactivation of E2F1. Hence,
our data reveal a novel function for AIB1 during or after
S-phase, in addition to its role during G1 progression where
it coactivates E2F [21] and favors cyclin D1 transcription [18].
To further study the molecular characteristics of AIB1-tg
cells, we isolated and cultured breast epithelium for no more
than two passages. We ﬁrst conﬁrmed the growth characteris-
tics of AIB1-tg cells by Laser Scanning Cytometry (LSC). As
expected, AIB1-tg primary cultures displayed a signiﬁcantreduction in the percentage of cells in G0/G1 and a corre-
sponding increase in the G2/M population, thereby supporting
the mammary hyperplasia observed in vivo (Fig. 4A). Similar
to previous reports [14], Western blot analysis from primary
cultures revealed an increase in the expression of cyclin D1
when AIB1 is overexpressed (Fig. 4B). This increase in cyclin
D expression was diminished when cultures were transfected
with small interference RNA for AIB1 (siAIB1). As a loading
control, we used antibodies against the epithelial speciﬁc
marker cytokeratin 14 (CK14). Interestingly, in cultures of
AIB1-tg epithelial cells, we also observed increased levels of
E-cadherin, an epithelial speciﬁc cell-to-cell adhesion molecule
that acts as a reservoir for b-catenin and is down-regulated in
many breast tumors. Transfection with siAIB1 also diminished
E-cadherin levels. Our results suggest that AIB1 may partici-
pate in the ER-mediated repression of the transcription factor
Snail [22] by releasing E-cadherin from Snail repression [23].
Interestingly, although loss of E-cadherin expression in epithe-
lial cells has been postulated to occur during the later stages of
tumorigenesis concomitant with the loss of epithelial features
[24–26], modest upregulation of this molecule by AIB1 may
represent another molecular change in early stages of abnor-
mal mammary growth. Snail is suﬃcient to promote mammary
tumor recurrence in vivo [27], and high levels of Snail predict
decreased relapsed-free survival in women with breast cancer.
AIB1 overexpression has also been associated with recurrence
due to tamoxifen resistance [28,29]. One interesting possibility
is that AIB1-mediated pre-tumor lesions require the additional
up-regulation of Snail to reduce E-cadherin levels.
Although these transgenic animals do not develop breast
tumors as has been observed in transgenic lines which over-
express AIB1 at high levels [14], they display mammary
hyperplasia from the onset of puberty, suggesting that they
may constitute a new model for investigating the early steps
of AIB1-induced breast cancer. Nuclear localization of AIB1
strongly correlated with BrdU incorporation, suggesting that
Fig. 3. Nuclear staining for AIB1 correlates with entry in S-phase of the cell cycle. (A) Double immunoﬂuorescence staining of mammary gland
tissue sections from 10-week-old (puberty) and 2 days nursing (lactation) WT and AIB1-tg littermates was performed, as indicated. Slides were
stained with polyclonal rabbit anti-AIB1 antibody (1:200; produced in our laboratory) that recognizes both AIB1 and endogenous p/CIP and with
anti-BrdU. (B) Positive BrdU nuclei were counted for concomitant nuclear AIB1 (open bars) or cytoplasmic AIB1 staining (stripped bars). Shown
are representative stainings of 3 WT and 3 AIB1-tg animals. *P = 10e6; **P = 10e3; ***P = 100e7; ****P = 10e3.
Fig. 4. Overexpression of AIB1 enhances cell-cycle progression and increases cyclin D1 and E-cadherin expression in mammary epithelial cultures.
(A) Primary epithelial cells were seeded in chamber slides (5000 cells/cm2) and grown for two days prior to LSC analysis. *P = 0.0004; **P = 0.14;
***P = 0.04. Shown is a representative of three independent experiments. (B) Representative Western blot showing increased cyclin D1 and
E-cadherin levels in AIB1-tg cells. Four mice of each genotype were used for cell preparations. Blots were probed with the antibodies indicated and
developed with chemiluminescent detection system (GE Healthcare).
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phase of the cell cycle and this mechanism remains unaltered
in the transgenic animals. Taken all together, our observations
suggest that low-level overexpression of AIB1 may predispose
for breast cancer development, but that additional genetic–
epigenetic alterations are required to progress from pre-neo-
plastic changes in mammary epithelium to pathological stagesof breast cancer. In fact, AIB1 overexpression is frequent in
the precursor lesions of pancreatic adenocarcinoma [11]. Thus,
our results support the idea that AIB1 may also contribute to
the early stages of breast cancer. Identiﬁcation of the addi-
tional alterations which are required in this progression from
epithelial hyperplasia to cancerous growth will help to predict
the clinical outcome of breast tumors including the response to
5226 A´. Avivar et al. / FEBS Letters 580 (2006) 5222–5226established therapies. Therefore, these new pathways which
interact with AIB1 during tumor progression constitute poten-
tial targets for improving both diagnostic tools and therapies
for breast cancer.
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